24 completed, 3 terminated, 3 unknown, 2 withdrawn. 14 Phase 2, 11 Phase 3, 6 Phase 4, 3 Not applicable, 1 Early Phase 1.
Follow this drug Literature Review of Apomorphine trials Research Report on Apomorphine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease Apomorphine - Parkinson Disease | Phase 4 | Completed | Rennes University Hospital | 19 | 2021-09-16 | 2025-05-30 |
| Apomorphine in Severe Brain-injured Patients Apomorphine Hydrochloride 5mg/ml, Sodium chloride 9mg/ml - Disorder of Consciousness | Phase 2 / Phase 3 | Recruiting | University of Liege | 48 | 2021-06-18 | 2025-04-15 |
| Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals Apomorphine, Dopaminergic Agonist + Apomorphine - Parkinson Disease | Not applicable | Completed | Rennes University Hospital | 43 | 2019-05-15 | 2023-11-27 |
| A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) APL-130277, subcutaneous apomorphine - Motor OFF Episodes Associated With Parkinson's Disease | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 113 | 2018-12-19 | 2022-12-16 |
| Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Apomorphine - Progressive Supranuclear Palsy, Corticobasal Degeneration | Completed | Fondation Ophtalmologique Adolphe de Rothschild | 7 | 2018-12-01 | 2021-03-08 | |
| Treating Severe Brain-injured Patients With Apomorphine Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe - Disorder of Consciousness | Phase 2 | Unknown | University of Liege | 8 | 2018-10-03 | 2022-02-09 |
| A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes APL-130277, APO-go, Apokyn - Parkinson Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 8 | 2017-08-22 | 2020-08-13 |
| A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes APL-130277, Placebo, Moxifloxacin - Parkinson's Disease, Off Episodes of Parkinson Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 48 | 2017-08-03 | 2020-08-10 |
| Apomorphine in Parkinson's Disease Patients With Visual Hallucinations Apomorphine, Placebo - Parkinson's Disease, Hallucinations, Visual | Phase 2 | Unknown | University Medical Center Groningen | 35 | 2017-05-01 | 2017-05-03 |
| Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP) Apomorphine, Best Medical Treatment - Parkinson's Disease | Phase 3 | Completed | Rennes University Hospital | 134 | 2017-03-03 | 2026-06-16 |
| Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Apomorphine, Placebo - Parkinson Disease | Phase 4 | Completed | Clinique Beau Soleil | 45 | 2017-01-31 | 2024-04-25 |
| Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Apomorphine - Parkinson's Disease | Phase 4 | Terminated | Fondation Ophtalmologique Adolphe de Rothschild | 15 | 2016-09-05 | 2018-03-26 |
| Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® APOKYN, Physical Therapy - Parkinson's Disease, Motor Symptoms | Phase 4 | Terminated | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 13 | 2016-01-01 | 2023-09-01 |
| Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease APL-130277 - Parkinson Disease | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 496 | 2015-08-31 | 2023-11-22 |
| Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease APL-130277, Placebo - Parkinson Disease, Off Episodes | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 141 | 2015-06-18 | 2020-07-30 |
| Treatment of Apomorphine-induced Skin Reactions: a Pilot Study Apomorphine 0.25% (2.5mg/ml), Massage with a spiky ball, Hydrocortisone cream 1% - Parkinson's Disease, Apomorphine-induced Skin Reactions | Phase 2 | Terminated | University Medical Center Groningen | 13 | 2015-06-01 | 2024-03-13 |
| A Study to Examine APL-130277 in Patients With Parkinson's Disease APL-130277 - Parkinson's Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 20 | 2014-08-31 | 2020-07-30 |
| Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease Apomorphine hydrochloride, Placebo - Parkinson's Disease | Phase 3 | Completed | Britannia Pharmaceuticals Ltd. | 107 | 2014-03-03 | 2019-07-08 |
| Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) APOKYN, L-dopa, Trimethobenzamide - Parkinson's Disease, Motor Symptoms | Phase 4 | Completed | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 127 | 2012-12-01 | 2023-08-14 |
| The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain Apomorphine, Normal Saline - Chronic Low Back Pain | Phase 4 | Completed | Rambam Health Care Campus | 59 | 2012-12-01 | 2016-11-22 |
Showing 20 of 34. Sign in to see all of them.
Parkinson Disease (26) · Persistent Vegetative State (3) · Consciousness Disorders (2) · Dyskinesias (2) · Pain (2) · Alcoholism (1) · Brain Injuries (1) · Brain Injuries, Traumatic (1) · Coma (1) · Corticobasal Degeneration (1) · Epilepsy (1) · Epilepsy, Idiopathic Generalized (1) · Hallucinations (1) · Recurrence (1) · Sleep Initiation and Maintenance Disorders (1)
Sumitomo Pharma America, Inc. (6) · Mylan Bertek Pharmaceuticals (4) · Rennes University Hospital (3) · Fondation Ophtalmologique Adolphe de Rothschild (2) · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (2) · Oregon Health and Science University (2) · Rambam Health Care Campus (2) · University Medical Center Groningen (2) · University of Liege (2) · Britannia Pharmaceuticals Ltd. (1) · Clinique Beau Soleil (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Kyowa Kirin Co., Ltd. (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (13) · France (11) · Spain (6) · Germany (4) · Italy (4) · United Kingdom (4) · Austria (3) · Canada (3) · Netherlands (3) · Belgium (2) · Israel (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Chile (1)
Will Sullivan (4) · Elon Eisenberg, MD (2) · John G. Nutt, MD (2) · Steven Laureys, M.D., Ph.D. (2) · Elkan R Gamzu, PhD (1) · Gianpiera H. Ceresoli-Borroni, PhD (1) · Jonathan Willmer, MD (1) · Mark Pirner, MD (1) · Miquel Casas, Prof (1)
PMID 18268187, PMID 18442107, PMID 18591063, PMID 19524477, PMID 19740486, PMID 20962287, PMID 21921019, PMID 23934921, PMID 25382161, PMID 26474316, PMID 26709292, PMID 30055903, PMID 30941094, PMID 31818699, PMID 33486139, PMID 33991326, PMID 34218046, PMID 35429481, PMID 35899977, PMID 39624459
2016 (3), 2015 (1), M01RR000334 (1), R01NS021062 (1)